A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human (Q41630579)

5 October 2017

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human (English)

1 reference

Mycobacterium tuberculosis

5 October 2017

0 references

Peter Andersen

16

0 references

Else Marie Agger

13

object named as

Else Marie Agger

1 reference

5 October 2017

14

Tom H M Ottenhoff

1 reference

5 October 2017

5

Corine Prins

1 reference

5 October 2017

2

Simone A Joosten

1 reference

5 October 2017

Jaap T van Dissel

1

1 reference

5 October 2017

Søren T Hoff

3

1 reference

5 October 2017

Darius Soonawala

4

1 reference

5 October 2017

David A Hokey

6

1 reference

5 October 2017

Dawn M O'Dee

7

1 reference

5 October 2017

Andrew Graves

8

1 reference

5 October 2017

Birgit Thierry-Carstensen

9

1 reference

5 October 2017

Lars V Andreasen

10

1 reference

5 October 2017

Morten Ruhwald

11

1 reference

5 October 2017

Adriëtte W de Visser

12

1 reference

5 October 2017

Ingrid Kromann

15

1 reference

5 October 2017

language of work or name

English

0 references

publication date

30 October 2014

1 reference

5 October 2017

1 reference

5 October 2017

32

1 reference

5 October 2017

7098-7107

1 reference

5 October 2017

52

1 reference

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations

5 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Vaccines against tuberculosis: where are we and where do we need to go?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Vaccination against tuberculosis: how can we better BCG?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Liposome-based cationic adjuvant formulations (CAF): past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

New pathways of protective and pathological host defense to mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

OMIP-022: Comprehensive assessment of antigen-specific human T-cell functionality and memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Vaccine adjuvants: current state and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Immunological biomarkers of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

T-cell quality in memory and protection: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

IL-13-producing Th1 and Th17 cells characterize adaptive responses to both self and foreign antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Tuberculosis subunit vaccines: from basic science to clinical testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

Diagnosis and treatment of latent infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.10.036

10.1016/J.VACCINE.2014.10.036

7 January 2021

Identifiers

DOI

1 reference

5 October 2017

1 reference